BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts collectively rate BioMarin “Moderate Buy,” with 15 buys, eight holds and one strong buy among 24 firms. The average 12-month price target is $88, though targets range widely from $50 to $124.
• BioMarin reported strong quarterly results, with revenue rising 20% year over year to about $990 million and earnings of $1.20 per share, beating consensus estimates. Management also raised its outlook, including 2026 VOXZOGO revenue guidance of at least $1 billion.
• VOXZOGO’s regulatory progress could expand BioMarin’s long-term growth opportunity, while recent insider sales totaling roughly $3 million and mixed analyst views remain potential concerns for investors.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty-four ratings firms that are covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $88.00.

BMRN has been the topic of several analyst reports. UBS Group reissued a "neutral" rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. Royal Bank Of Canada lowered their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating for the company in a research report on Tuesday, July 7th. Morgan Stanley upped their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Oppenheimer raised their price objective on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an "outperform" rating in a research note on Friday. Finally, Sanford C. Bernstein decreased their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an "outperform" rating for the company in a report on Tuesday, May 5th.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Canaccord raised its price target to $114 from $111 and reiterated a Buy rating, implying substantial potential upside from recent trading levels. Canaccord price target increase
• Positive Sentiment: Morgan Stanley maintained its Buy rating, reinforcing bullish sell-side sentiment. BioMarin’s second-quarter revenue rose 20% year over year to approximately $990 million, beating expectations, while management increased full-year guidance. VOXZOGO remained a key growth driver, with 2026 revenue guidance lifted to at least $1 billion. Morgan Stanley Buy rating
• Positive Sentiment: Recent regulatory progress for VOXZOGO—including FDA acceptance of a supplemental application for full approval in children with achondroplasia—could expand the product’s long-term commercial opportunity.
• Neutral Sentiment: BioMarin will present at the Canaccord Genuity Growth Conference on August 12. The event could provide additional updates on the company’s pipeline, VOXZOGO demand and financial outlook, but no new information has yet been announced. Canaccord conference announcement
• Neutral Sentiment: Analyst views remain mixed, with published price targets ranging from $50 to $124 and a median of $83.50. A report also showed 263 institutions adding shares versus 271 reducing positions, indicating balanced institutional activity. Analyst views on BioMarin
• Negative Sentiment: Three BioMarin executives reported open-market sales totaling roughly $3.0 million over the past six months, with no reported insider purchases. While these transactions may be routine, the absence of insider buying provides limited additional confirmation of the rally.
• Neutral Sentiment: A short-interest update listed zero shares short and a zero-day days-to-cover ratio, but the reported percentage change was unavailable, making the data unreliable and unlikely to be a meaningful trading signal.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN. Swedbank AB boosted its stake in shares of BioMarin Pharmaceutical by 70.6% during the 4th quarter. Swedbank AB now owns 796,737 shares of the biotechnology company's stock worth $47,350,000 after acquiring an additional 329,794 shares during the last quarter. LSV Asset Management increased its stake in shares of BioMarin Pharmaceutical by 4.3% in the 4th quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company's stock worth $52,429,000 after purchasing an additional 36,700 shares in the last quarter. C WorldWide Group Holding A S increased its stake in shares of BioMarin Pharmaceutical by 12.6% in the 4th quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company's stock worth $15,918,000 after purchasing an additional 30,000 shares in the last quarter. KBC Group NV raised its holdings in BioMarin Pharmaceutical by 10.0% in the 4th quarter. KBC Group NV now owns 168,779 shares of the biotechnology company's stock worth $10,031,000 after purchasing an additional 15,362 shares during the period. Finally, Horizon Investments LLC lifted its position in BioMarin Pharmaceutical by 22.3% during the fourth quarter. Horizon Investments LLC now owns 99,681 shares of the biotechnology company's stock valued at $5,924,000 after purchasing an additional 18,143 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Trading Up 1.0%

NASDAQ:BMRN opened at $69.55 on Wednesday. The firm has a market capitalization of $13.46 billion, a P/E ratio of 187.97, a PEG ratio of 0.48 and a beta of 0.24. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.62. The company's 50-day simple moving average is $58.80 and its 200 day simple moving average is $57.26.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. During the same quarter last year, the firm earned $1.44 earnings per share. The business's revenue for the quarter was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, analysts forecast that BioMarin Pharmaceutical will post 4.22 EPS for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source